Friday, January 06, 2023 10:18:05 PM
You're correct about it being an excellent presentation. In discussing the long term survivors from as far back as the Phase 1 I believe the Drs. discussed benefits I've not heard discussed before, even if we knew they existed. I also liked the fact that they discussed being able to get the vaccine under compassionate use in the U.K.
It's sad that commercial production appears to be what's preventing making the vaccine available to more people sooner. I suspect that if compassionate use were available here in the U.S. as it is in the U.K., far more people would be willing to pay for it provided they didn't have to move to get it.
For now, nothing should be of higher priority than gaining approval of the Flaskworks unit. I would still suspect that the list price for the vaccine will be nearly what's being paid in the U.K. for compassionate use, the huge difference will be that insurance will cover the burden, not the individual patient. I'm not certain that if a patient here filed suit against their insurance here they couldn't force at least partial payment for the drug from the U.K. given what the Drs. had to say about it.
Gary
It's sad that commercial production appears to be what's preventing making the vaccine available to more people sooner. I suspect that if compassionate use were available here in the U.S. as it is in the U.K., far more people would be willing to pay for it provided they didn't have to move to get it.
For now, nothing should be of higher priority than gaining approval of the Flaskworks unit. I would still suspect that the list price for the vaccine will be nearly what's being paid in the U.K. for compassionate use, the huge difference will be that insurance will cover the burden, not the individual patient. I'm not certain that if a patient here filed suit against their insurance here they couldn't force at least partial payment for the drug from the U.K. given what the Drs. had to say about it.
Gary
Bullish
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
